CTCL

AcronymDefinition
CTCLCutaneous T Cell Lymphoma
CTCLColleges That Change Lives (college search resource; Westminster, MD)
CTCLCareless Talk Costs Lives (magazine)
CTCLCentral Texas Cricket League (est. 2002)
CTCLCiticorp Trustee Company Limited (London, England, UK)
CTCLChina Telecom Corporation Ltd.
CTCLComputer to Computer Link (investing)
References in periodicals archive ?
Based on audits so far, the agency might greenlight mogamulizumab for previously treated CTCL by early 2018--its first approval in the United States, Dr.
It was the largest global randomised clinical trial of systemic therapy in CTCL.
We plan to submit the data to regulatory bodies around the world, and if approved, ADCETRIS would be a potential new treatment option for patients with CD30-positive CTCL, a rare, debilitating and often difficult to treat form of cancer, said Dirk Huebner, M.
While CTCL is the biggie in the differential diagnosis of very-late-onset atopic dermatitis, other conditions that need to be considered include psoriasis, contact dermatitis, pityriasis rubra pilaris, and pityriasis rosea.
The frequency of each subtype of primary CTCL (new WHO-EORTC classification) is shown in Table 2.
The emergence of systemically administered HDACi inhibitors has proven to be a significant advance in the treatment of CTCL, particularly for patients with more advanced disease.
CTCL was established in 1975 as a closely held public limited company.
Results showed that 27/37 (73%) patients with CTCL responded to therapy with ECP, with erythrodermic patients having an overall response rate of 83% (17).
Completion of patient enrollment in this landmark study is a major milestone in our efforts to advance Clearazide through regulatory approval and to help patients with CTCL.
The study enrolled a total of 144 patients with CTCL whose malignant cells expressed the CD25 component of the IL-2 receptor.
Food and Drug Administration for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent or recurrent disease on or following two systemic therapies.